Skip to main content
Recent Quotes
My Watchlist
Indicators
Markets
Stocks
ETFs
Tools
Markets:
Overview
News
Currencies
International
Treasuries

Precigen, Inc. - Common Stock (NQ:PGEN)

5.420 -1.520 (-21.90%)
Delayed Quote Updated: 3:26 PM EST, Nov 2, 2026 Add to My Watchlist
Quote
Overview Detailed Quote Charting Historical Prices
News
All News News Headlines Press Releases
Research
Quarterly Reports Insider Filings Other Filings

All News about Precigen, Inc. - Common Stock

< Previous 1 2 3 4 5 6 7 Next >
Premarket Movers Nov. 2, 2026: Gainers and Losers ↗
Via Chartmill
Postmarket Movers: After-Hours Gainers and Losers ↗
Via Chartmill
News headline image
Precigen's Strong Second Quarter Signals Significant Growth, Validates AdenoVerse Platform; PRGN-2009 Advances in HPV-Driven Cancers
From Precigen, Inc.
Via ACCESS Newswire
News headline image
Precigen (PGEN) Q2 2026 Earnings Call Transcript ↗
PAPZIMEOS revenue surged 145.8% sequentially as company posts first profitable quarter. 
Via The Motley Fool
Topics Earnings
Precigen Inc (NASDAQ:PGEN) Flashes Perfect Technical Rating and Explosive Sales Growth in Minervini Screen ↗
Via Chartmill
Precigen Inc (NASDAQ:PGEN) Stock Surges on Narrower Loss and Commercial Transition After FDA Approval ↗
Via Chartmill
Precigen Stock Up 280% in a Year — Is FDA Approval Behind This Big New Investor Bet? ↗
Via The Motley Fool
News headline image
Precigen Q2 Earnings Call Highlights ↗
Precigen (NASDAQ:PGEN) reported a sharp increase in second-quarter revenue from its PAPZIMEOS launch, with the company reaching quarterly profitability less than a year after the therapy’s August 2025... 
Via MarketBeat
Topics Earnings
What's going on in today's after hours session ↗
Via Chartmill
News headline image
What Does the Sale of Precigen Shares Worth $1.1 Million by the CFO Mean for Investors? ↗
Focused on gene and cellular therapies, this biotech firm reported a notable insider sale amid a year of rapid share price gains. 
Via The Motley Fool
Topics Regulatory Compliance
News headline image
Precigen Gains Advantage as PAPZIMEOS Granted Orphan Drug Exclusivity by FDA; Long-Term Data From Clinical Study Encouraging
Via ACCESS Newswire
News headline image
Earnings Scheduled For November 13, 2025 ↗
 
Via Benzinga
News headline image
Is Precigen (PGEN) a Stock to Sell After Its CFO Let Go of 41,000 Shares? ↗
Focused on gene and cell therapies, this biotech innovator reported a notable insider sale amid a year of exceptional share price gains. 
Via The Motley Fool
Topics Regulatory Compliance
News headline image
Precigen Q1 Earnings Call Highlights ↗
Precigen (NASDAQ:PGEN) reported a sharp increase in first-quarter 2026 revenue as the company’s first commercial product, PAPZIMEOS, continued its U.S. launch following FDA approval in August 2025. On... 
Via MarketBeat
Topics Earnings
News headline image
Precigen (PGEN) Q1 2026 Earnings Transcript ↗
Precigen (PGEN) Q1 2026 Earnings Transcript 
Via The Motley Fool
News headline image
Precigen Reports 'Robust Uptake' of New Drug for Rare Respiratory Disease; First Quarter Revenue Expected to Top $18 Million
Via ACCESS Newswire
News headline image
These Analysts Boost Their Forecasts On Precigen Following Q4 Results ↗
Precigen, Inc. (NASDAQ:PGEN) reported mixed Q4 results, with a loss of 1 cent per share beating estimates but sales of $4.565 million falling short. 
Via Benzinga
Thursday's session: gap up and gap down stocks ↗
Via Chartmill
These stocks that are showing activity before the opening bell on Thursday. ↗
Via Chartmill
Stay updated with the stocks that are on the move in today's after-hours session. ↗
Via Chartmill
News headline image
Precigen (PGEN) Q4 2025 Earnings Call Transcript ↗
Precigen (PGEN) Q4 2025 Earnings Call Transcript 
Via The Motley Fool
Topics Earnings
News headline image
Inside One Fund's $21 Million Bet on Hilton Grand Vacations Stock ↗
This vacation ownership firm serves over 700,000 members and generates recurring revenue from real estate, financing, and resort operations. 
Via The Motley Fool
News headline image
Top movers analysis one hour before the close of the markets on 2025-11-14: top gainers and losers in today's session. ↗
Here are the top movers in Friday's session, showcasing the stocks with significant price changes. 
Via Chartmill
News headline image
12 Health Care Stocks Moving In Friday's Intraday Session ↗
 
Via Benzinga
News headline image
Precigen Inc (NASDAQ:PGEN) Q3 2025 Earnings: Revenue Soars But Wider Loss Dampens Investor Sentiment ↗
Precigen's Q3 2025 results show a huge revenue beat but a wider-than-expected loss. The key highlight is the full FDA approval and launch of its new therapy, PAPZIMEOS. 
Via Chartmill
News headline image
Precigen (PGEN) Q3 2025 Earnings Call Transcript ↗
Precigen (PGEN) Q3 2025 Earnings Call Transcript 
Via The Motley Fool
Topics Earnings
News headline image
Exploring Precigen's Earnings Expectations ↗
 
Via Benzinga
News headline image
Patient Capital Bets Big on Precigen (PGEN) By Acquiring 10.2 Million Shares ↗
Patient Capital Bets Big on Precigen (PGEN) By Acquiring 10.2 Million Shares 
Via The Motley Fool
News headline image
These 2 Healthcare Stocks More Than Doubled Recently and Could Soar Higher, According to Wall Street Analysts ↗
Experts who follow these stocks think they can fly higher despite already gaining over 100% since the end of July. 
Via The Motley Fool
News headline image
Macy's Increases FY2025 Outlook, Joins REV Group, HealthEquity, Alphabet and Wellness And Other Big Stocks Moving Higher On Wednesday ↗
 
Via Benzinga
< Previous 1 2 3 4 5 6 7 Next >
Stock Quote API & Stock News API supplied by www.cloudquote.io
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the Privacy Policy and Terms Of Service.
© 2025 FinancialContent. All rights reserved.